Amendments to the Specification

In reference to the Notice of Allowability dated 04/06/2005, and the Examiner's Amendment (pgs. 4-5) of the specification of the paragraph at page 6, line 15 to page 7, line 1 beginning "The term "pharmaceutically acceptable carrier",..." , please replace this amended paragraph with the following paragraph:

The term "pharmaceutically acceptable carrier", when used herein for purposes of the specification and claims, means a carrier medium that does not significantly alter the biological activity of the active ingredient (e.g., a synthetic peptide comprising an HIV-fusion inhibitor) to which it is added. In accordance with the present invention, a polyol is a pharmaceutically acceptable carrier in the pharmaceutical composition comprising an injectable aqueous formulation according to the present invention. The pharmaceutical composition may comprise one or more additional pharmaceutically acceptable carriers other than polyol contained therein (i.e., one or more pharmaceutically acceptable carriers in addition to the polyol). As known to those skilled in the art, and for use in an injectable solution or aqueous formulation, a suitable pharmaceutically acceptable carrier may comprise one or more substances, including but not limited to, water, buffered water, saline, 0.3% glycine, aqueous alcohols, isotonic aqueous buffer; and may further include one or more substances such as glycerol, oils, salts such as sodium, potassium, magnesium and ammonium, phosphonates, carbonate esters, fatty acids, saccharides (e.g., mannitol), polysaccharides, excipients, and preservatives and/or stabilizers (to increase shelf-life or as necessary and suitable for manufacture and distribution of the composition). Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous or parenteral administration (e.g., by injection).